Ovarian Cancer: More Women Benefit from Maintenance Combined Targeted Therapy #ESMO19

da Salute H24 — 28 settembre 2019 alle 12:17


New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. Continua »

AntonioCaperna

Scrivi un commento